Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 265-271

  Tiseo, Marcello ^a   Andreoli, Roberta ^a,b   Gelsomino, Francesco ^a   Mozzoni, Paola ^a,b   Azzoni, Cinzia ^a   Bartolotti, Marco ^a   Bortesi, Beatrice ^a   Goldoni, Matteo ^a,b   Silini, Enrico Maria ^a   De Palma, Giuseppe ^c   Mutti, Antonio ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Erlotinib; NSCLC; Pharmacokinetic; Skin toxicity

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; URINALYSIS; URINE LEVEL;

ERLOTINIB; NSCLC; PHARMACOKINETIC; SKIN TOXICITY;

AGED; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; HYDROCORTISONE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; SKIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84892893614     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.001     Document Type: Article

References (37)

1. Shepherd F.A., Rodriguez Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
2. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
4. Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
5. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled, phase III study. Lancet Oncol 2010, 11:521-529.
6. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
7. Wackner B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P.J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
8. Tiseo M., Gridelli C., Cascinu S., Crinò L., Piantedosi F.V., Grossi F., et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer 2009, 64:199-206.
9. Mohamed M.K., Ramalingam S., Lin Y., Gooding W., Belani C.P. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005, 16:780-785.
10. Petrelli F., Borgonovo K., Cabiddu M., Lonati V., Barni S. Relationship between skin rash and out come in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012, 8:8-15.
11. Hidalgo M., Siu L.L., Nemunaitis J., Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
12. Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005, 23:5235-5246.
13. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22:77-85.
14. Cunningham D., Humblet Y., Siena S., Hayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
15. Laux I., Jain A., Singh S., Agus D.B. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006, 94:85-92.
16. Rudin C.M., Liu W., Desai A., Karrison T., Jiang X., Janisch L., et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26:1119-1127.
17. Hughes A.N., O'Brien M.E.R., Petty W.J., Chick J.B., Rankin E., Woll P.J., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009, 27:1220-1226.
18. Erlotinib. http://www.roche.com/products/productdetails.htm.
19. Therasse P., Arbuck S.G., Esenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
20. Kraut E.H., Rhoades C., Zhang Y., Cheng H., Aimiumu J., Chen P., et al. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer Chemother Pharmacol 2011, 67:579-586.
21. Persichilli S., Gervasoni J., Iavarone F., Zuppi C. A simple liquid chromatography-tandem mass spectrometry method for urinary free cortisol analysis: suitable for routine purpose. Clin Chem Lab Med 2010, 48:1433-1437.
22. Tiseo M., Rossi G., Capelletti M., Sartori G., Spiritelli E., Marchioni A., et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of comprehensive panel of molecular markers. Lung Cancer 2010, 67:355-360.
23. Lee Y., Shim H.S., Park M.S., Kim J.H., Ha S.J., Kim S.H., et al. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res 2012, 18:1760-1768.
24. Lee S.M., Khan I., Upadhyay S., Lewanski C., Falk S., Skailes G., et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012, 13:1161-1170.
25. Mita A.C., Papadopoulos K., de Jong M.J.A., Schwartz G., Verweij J., Mita M.M., et al. Erlotinib "dosing-to-rash": a phase II intra-patient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 2011, 105:938-944.
26. Amador M.L., Oppenheimer D., Perea S., Maitra A., Cusatis G., Iacobuzio-Donahue C., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004, 64:9139-9143.
27. Tiseo M., Capelletti M., De Palma G., Franciosi V., Cavazzoni A., Mozzoni P., et al. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1104-1111.
28. Mir O., Blanchet B., Goldwasser F. Drug-induced effects on erlotinib metabolism. N Engl J Med 2011, 365:379-380.
29. Cataldo V.D., Gibbons D.L., Perez-Soler R., Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364:947-955.
30. Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
31. Fukudo M., Ikemi Y., Togashi Y., Masago K., Kim Y.H., Mio T., et al. Population pharmacokinetics and pharmacogenomics of erlotinib: effect of drug exposure on treatment outcomes in Japanese patients with non-small cell lung cancer. J Clin Oncol 2011, 29. [Suppl.; abstract 2549].
32. White-Koning M., Civade E., Geoerger B., Thomas F., Le Deley M.C., Hennebelle I., et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin Cancer Res 2011, 17:4862-4871.
33. Gao B., Yeap S., Clements A., Balakrishnar B., Wong M., Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012, 30:4017-4025.
34. Jing L., Ming Z., Ping H., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007, 13:3731-3737.
35. Hamada A., Sasaki J., Saeki S., Iwamoto N., Inaba M., Ushijima S., et al. Metabolic profiles as predictive biomarkers of erlotinib-induced adverse effects in patients with non-small cell lung cancer. J Clin Oncol 2011, 29. (Suppl.; abstract 2549).
36. Foo J., Chmielecki J., Pao W., Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol 2012, 7:1583-1593.
37. Nakamura Y., Kazumi S., Hiroshi S., Takatani H., Fukuda M., Nagashima S., et al. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 2010, 5:1404-1409.